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Abstract
In recent years, immunomodulatory agents, such as monoclonal antibodies (mAbs), have been effectively utilized in the management of
several malignancies, in transplant rejection, in autoimmune and inﬂammatory diseases, and in a range of further indications. However,
the administration of mAbs is associated with an increased risk of infections, in particular of viral infections, that is not fully appreciated.
The inﬂuence of mAbs on viral infections is likely to be relevant, impacting on the incidence, severity and timing of infections. Some of
these viral infections may result in treatment delays and may be coupled with increased morbidity and mortality. Although all viral infec-
tions presumably play an important role in patients undergoing mAb treatment, and may affect outcome, some are more common than
others, e.g. hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus, varicella-zoster virus and Epstein–Barr virus infections.
This review focuses on the viral infections of primary clinical relevance, such as HBV, HCV, and herpesvirus infections, that may occur
in patients undergoing immunomodulatory treatment.
Keywords: immunosuppression, infectious risks, monoclonal antibodies, outcomeviruses
Article published online: 21 September 2011
Clin Microbiol Infect 2011; 17: 1769–1775
Corresponding author: G. Gentile, Haematology, Department of
Cellular Biotechnologies and Haematology, ‘Sapienza’ University, V.
Benevento 6, 00161 Rome, Italy
E-mail: gentile@bce.uniroma1.it
Introduction
The number of monoclonal antibodies (mAbs) and other bio-
logical therapies targeted at components of the immune sys-
tem continues to expand. Data obtained from both clinical
studies and post-marketing surveillance have shown that
these agents may enhance susceptibility to infections.
Increased rates of bacterial and mycobacterial infections have
been observed among patients receiving mAbs and other
biological therapies, and attention has recently been given to
the risks of opportunistic infections, including Pneumocystis
jirovecii infection and invasive mycoses [1,2]. However, the
relationship between mAb treatment and the risk of viral
infection is less well appreciated.
Some viruses are capable of establishing chronic infections
(e.g. hepatitis B virus (HBV) and hepatitis C virus (HCV))
and exist in a latent form with the potential to reactivate fol-
lowing alterations of the host immune status (e.g. members
of the human herpesvirus (HHV) family), whereas some of
them are associated with an increased risk of malignancy
(e.g. Epstein–Barr virus (EBV) and HHV-8)). Such infections
may have implications for the screening and surveillance of
patients prior to, during and after mAb treatment.
Patients who receive immunomodulating biological thera-
pies are usually at a higher risk of developing infections, given
their underlying disease, and the prior and concurrent treat-
ment with other immunosuppressive agents. Therefore, one
of the major problems in determining a causal relationship
between biological therapy and infection is the fact that the
underlying disease process itself, along with other immuno-
suppressive therapy administered previously or concurrently,
can cause a state of immunosuppression. This is the case for
patients with cancer, autoimmune diseases, and inﬂammatory
conditions. In addition, in the event of rare infections, a
strong association is difﬁcult to prove, because of the small
number of events observed. Even in randomized placebo-
controlled trials and in large open-label studies, it is difﬁcult
to attribute the increased risk of infection to the mAbs alone,
because of the large number of confounders observed [3,4].
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In this article, we review the literature regarding the asso-
ciation between viral infection (e.g. HBV, HBC and herpes-
virus infections) and mAb therapies, and discuss strategies
for the screening, detection, prevention and treatment of
these viral infections.
HBV
Reactivation of HBV infection is a well-described complica-
tion in the setting of cancer chemotherapy and in stem cell
or organ transplantation, occurring in up to 50% of patients
who do not receive anti-HBV drugs [5,6]. Mortality from
liver failure after reactivation of HBV in patients receiving
chemotherapy is reported in 4–60% of cases [7]. The risk of
HBV reactivation is greater in patients with a high level of
HBV replication at baseline, in patients with lymphoma, and
in patients receiving chemotherapy regimens including corti-
costeroids or rituximab-based therapy [7]. Also, tumour
necrosis factor (TNF)-a inhibitors, such as inﬂiximab, etaner-
cept, and adalimumab, may cause reactivation of HBV, even
though the overall frequency of reactivation of HBV seems
to be lower than with cancer chemotherapy.
HBV reactivation is usually subclinical, but can result in
severe disease, including acute liver failure and death [5–8].
Recommendations have therefore been published [5,9,10]
calling for universal screening for HBV infection with hepati-
tis B surface antigen (HBsAg) for all patients undergoing
immunosuppressive treatment or chemotherapy. The Ameri-
can Society for the Study of Liver Disease and the European
Association for the Study of the Liver recommend anti-HBV
prophylaxis with nucleoside/nucleotide analogues for all
patients with positive HBsAg receiving immunosuppression
or chemotherapy, because this strategy drastically reduces
HBV reactivation, hepatitis, and death [5,9]. Lamivudine has
proven efﬁcacy and safety in preventing HBV reactivation fol-
lowing chemotherapy for both haematological and solid
malignancies [11]. A major concern with its prolonged use is
the possibility of viral breakthrough following the emergence
of resistance mutations (up to 24% at 1 year and 60% at
3 years) in the YMDD region of HBV DNA polymerase. Pro-
phylaxis should begin 1 week prior to chemotherapy and
should be maintained for at least 6–12 months after the end
of immunosuppression, as HBV reactivation may occur after
chemotherapy is discontinued [5,9,10]; lamivudine (100 mg
orally once daily) should be administered to patients with
low or undetectable HBV DNA levels at baseline, who will
receive treatment for <1 year, whereas in patients with high
HBV DNA levels (>2000 IU/mL) at baseline, who will receive
anti-HBV prophylaxis for more than 1 year, new, more
potent, drugs with less risk of resistance, such as tenofovir
(300 mg orally once daily) and entecavir (for nucleoside-
naı¨ve patients, 0.5 mg daily orally, and for lamivudine-refrac-
tory/resistant patients, 1 mg daily orally), should be used
[5,9]. With regard to patients with serological markers of a
past HBV infection (HBsAg-negative and anti-hepatitis B core
(HBcAb)-positive) undergoing immunosuppression or chemo-
therapy, the strategy is less clear. HBV reactivation for
patients with resolved infection frequency is lower for
HBsAg-positive patients, but for haematological patients
receiving prolonged and intensive immunosuppression the
risk is high and associated with a high mortality rate [12].
The American Society for the Study of Liver Disease [5]
guidelines suggest quantiﬁcation of HBV DNA in the serum,
and, if it is undetectable, frequent follow-up by means of
transaminase and HBV DNA testing. Currently, the Italian
Society for the Study of Liver Disease advises anti-HBV pro-
phylaxis for HBsAg-negative/anti-HBcAb-positive patients at
risk of reactivation who have undetectable or low levels
(100 copies/mL) of HBV DNA [10].
In patients with haematological and solid malignancies who
develop HBV reactivation and have not received prophylactic
anti-HBV drugs, chemotherapy must be suspended and hepa-
totoxic drugs discontinued. Prompt administration of anti-
HBV therapy is vital. Lamivudine is effective for the treat-
ment of patients with HBV reactivation after chemotherapy;
however, the mortality rate of patients with HBV reactiva-
tion, once it has developed, remains high [13]. A better out-
come might be obtained if lamivudine or other more
effective anti-HBV drugs (tenofovir and entecavir) can be
promptly started at the time of the initial rise in HBV DNA,
before the viral load is too high [5].
To date, ﬁve TNF-a inhibitors have been approved by the
Food and Drug Administration in the USA: inﬂiximab, eta-
nercept, adalimumab, certolizumab, and golimumab. Several
of these agents are also approved for the treatment of anky-
losing spondylitis, as well as of non-rheumatological diseases
such as Crohn’s disease and psoriasis.
It is currently unknown whether HBV reactivation is a
class effect or attributable to a particular TNF-a inhibitor.
TNF-a is critically involved in the control of HBV replication
and in stimulating anti-HBV T-cell responses [14], and the
levels of TNF-a are elevated in patients with chronic HBV
infection [15].
The use of anti-TNF-a drugs and HBV infection has been
described in at least 30 patients (reviewed in [16]), and a
variety of outcomes, ranging from asymptomatic to fatal hep-
atitis, have been reported. The majority of patients treated
with anti-TNF-a drugs who did not receive concomitant
anti-HBV therapy showed increased viral loads and serum
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transaminases (alanine transaminase (ALT)), and many of
them developed hepatic dysfunction. The duration of anti-
TNF-a therapy prior to HBV reactivation was variable, from a
single dose to many months of maintenance treatment. The
majority of cases of HBV reactivation have been associated
with the more potent inﬂiximab or adalimumab rather than
with etanercept [16]. Prophylaxis prevents HBV reactivation
in HBsAg-positive patients receiving inﬂiximab [16]. There are
insufﬁcient data for routine prophylaxis with the use of etaner-
cept and adalimumab to be advised, but, until such data
become available, it seems prudent to administer prophylaxis.
Rituximab is a mAb that targets the CD20 antigen on the
surface of normal and malignant B-lymphocytes; CD20 is
present in up to 95% of B-cell non-Hodgkin lymphomas
(NHLs). Rituximab is effective in a variety of haematological
malignancies, both as a single agent and in combination with
chemotherapy. Rituximab is widely approved for the treat-
ment of B-cell NHL, as well as rheumatoid arthritis (RA)
refractory to TNF-a inhibitors. The off-label uses of ritux-
imab include treatment of autoimmune disorders, e.g. sys-
temic lupus erythematosus, idiopathic thrombocytopenia
purpura, and cryoglobulinaemia [16], and also solid organ
transplantation [17,18]. The administration of rituximab
results in a depletion of normal B-cells that may last for sev-
eral months following treatment; the levels of B-cells may
return to normal by 12 months after the end of treatment.
A possible relationship between rituximab and HBV may be
explained by the depletion of B-cells, which are crucial for
both T-cell-mediated and antibody-mediated immunity.
HBV reactivation has been consistently associated with rit-
uximab treatment in post-marketing reports, and has ranged
from 25% to 39% of the reported cases, resulting in a high
mortality rate of 52%, owing to hepatic failure [19–21]. If
HBV reactivation occurs, rituximab and any concomitant
chemotherapy should be discontinued; this results in antican-
cer treatment delays and in an inferior overall outcome. The
addition of rituximab to cyclophosphamide, doxorubicine,
vincristine and prednisone (CHOP) chemotherapy may
increase the risk of HBV reactivation, but the precise magni-
tude of the increase is not known [20].
HBV reactivation has been increasingly reported in patients
with resolved infection [20]. In a recent study of HBsAg-neg-
ative/anti-HBcAb-positive patients with NHL treated with rit-
uximab–CHOP, 25% developed HBV reactivation [21].
HCV
Levels of TNF-a appear to be elevated in HCV-positive
patients, and may be correlated with ALT levels, but the role
of TNF-a in the progression of hepatitis remains unclear
[22]. It is known that persistence and high levels of TNF-a,
even when HCV RNA becomes undetectable during treat-
ment, is associated with HCV relapse. TNF-a has been impli-
cated in refractoriness to interferon therapy in patients with
HCV. The mechanism by which TNF-a induces refractoriness
to interferon in these patients remains unknown. Data relat-
ing to the use of anti-TNF-a in the setting of HCV infections
are limited, but treatment with inﬂiximab and etanercept
appears to be relatively safe in HCV-positive patients, even if
the durations of treatment and follow-up are relatively short
(3–9 months) [22,23]. Anti-TNF-a therapy appears to be
safe, and it should be used with caution in patients with
chronic HCV infection. Patients should be followed closely
while they are receiving anti-TNF-a therapy, with regular
monitoring of ALT and of the HCV load.
The relationship between rituximab and HCV reactivation
has been explored in several reports. A recent multicentre,
retrospective Japanese study has demonstrated both the ben-
eﬁts and the risks of adding rituximab to CHOP chemother-
apy in patients with diffuse large B-cell lymphoma and HCV
infection [24]. HCV infection did not inﬂuence long-term
progression-free survival, but the incidence of severe hepatic
toxicity and the increase in HCV viral load in HCV-positive
patients were signiﬁcantly higher in HCV-negative patients.
Other studies showed a lack of correlation between levels
of HCV RNA and the extent of liver damage, and the vari-
ability in HCV RNA levels over time prevents ﬁrm conclu-
sions being drawn regarding the association of rituximab
with HCV infection and liver damage in patients with lym-
phoma [25,26]. Rituximab is being increasingly used for the
treatment of HCV-related cryoglobulinaemic vasculitis, and
the data from short-term studies show a clinical response,
without relevant liver toxicity, even though, in some individu-
als, a small increase in HCV RNA levels was observed during
treatment with rituximab [23]. Careful monitoring of hepatic
function and HCV RNA in patients who are HCV-positive
and receiving rituximab is recommended.
Herpesvirus Infections
Herpesvirus are common in the majority of populations, with
serological evidence of past exposure to herpes simplex
virus (HSV)-1, cytomegalovirus (CMV), EBV and varicella-
zoster virus (VZV) being found in 80–90% of the adult popu-
lation. Reactivation of herpesvirus infection is an important
problem in transplant patients and in human immunodeﬁ-
ciency virus-positive patients, leading to recommendations
regarding the prevention and management of this complica-
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tion [27,28]. TNF-a is critically involved in the regulation of
herpesvirus replication and dissemination, and experience
with anti-TNF-a agents has shown herpesvirus reactivation
to be relatively frequent in a number of cases, resulting in
serious adverse events [16].
HSV
Reactivation of HSV has not been clearly associated with
anti-TNF-a therapy. Occasional cases of HSV reactivation,
including cases of HSV oesophagitis, three cases of HSV
encephalitis, and one case of disseminated infection, in
patients treated with inﬂiximab or adalimumab have been
reported (reviewed in [16,29]).
VZV
VZV reactivation is well documented in patients receiving
anti-TNF-a therapy, and appears to be associated, in particu-
lar, with mAbs such as inﬂiximab and adalimumab [16,30].
Analysis of a large series of patients with RA treated with
anti-TNF-a therapy has shown an incidence of 11/
1000 patient-years of herpes zoster (HZ) with adalimumab
and inﬂiximab, 8.9/1000 patient-years with etanercept, and
5.6/1000 patient-years with conventional disease-modifying
anti-rheumatic therapy [30]. It is relevant to note that 18%
of cases were multidermatomal, 13% of cases required hospi-
talization, and 5% of these patients developed recurrences,
suggesting that HZ occurring in the setting of anti-TNF-a
therapy may be severe [30]. In patients developing HZ, anti-
TNF-a therapy should be interrupted, but can be safely
restarted when vesicles have resolved and anti-VZV therapy
with acyclovir or valaciclovir has been administered. Severe,
atypical primary varicella has been reported in patients
receiving anti-TNF-a therapy [16]. Attention should be given
to the serological VZV status of patients before the start of
immunosuppressive therapy. Vaccination is available, but a
live vaccine is contraindicated in patients receiving immuno-
suppressive therapy or anti-TNF-a drugs.
CMV
CMV active infection is still a frequent cause of morbidity
and mortality in immunocompromised patients and, in partic-
ular, in those undergoing solid organ and haematopoietic
stem cell transplantation (HSCT). The impact of CMV infec-
tion and disease is less clearly deﬁned for patients with hae-
matological malignancies who receive conventional
chemotherapy and/or mAbs, and for those patients receiving
mAbs and immunomodulating agents for other diseases
[16,19,20,31,32]. CMV disease manifestations include pneu-
monia, enteritis, encephalitis, retinitis, hepatitis, and marrow
suppression.
TNF-a is involved in controlling CMV replication in vitro,
but the role of anti-TNF-a therapy in these cases remains
speculative, because the majority of patients receive multiple
concomitant immunosuppressive drugs. Prospective studies
in Crohn’s disease and RA have shown no evidence of signiﬁ-
cant CMV reactivation, as measured by pp65 antigenaemia or
CMV PCR [16,33]. Similarly, inﬂiximab treatment does not
appear to affect colonic tissue viral load [33], even though
several cases of CMV disease complicating TNF-a therapy,
including pneumonia, have been reported [34]. Allogeneic
haematopoietic stem cell transplant recipients with severe
steroid refractory acute graft-versus-host disease (GVHD)
are at high risk of CMV reactivation. A rate of CMV reacti-
vation of 67% has been reported in these patients [35], most
likely because of the heavy concomitant immune depression;
the addition of anti-TNF-a therapy further increases the risk
of CMV infection.
Alemtuzumab, a humanized anti-CD52 mAb, binds to the
cell membranes of virtually all normal blood lymphocytes, as
well as to most malignant B-cells and T-cells, causing pro-
found and prolonged lymphopenia [36,37]. CD4 and CD8 T-
lymphocyte counts reach their nadir c. 4 weeks after ale-
mtuzumab administration, and lymphopenia may persist for
over 1 year [36,37]. Alemtuzumab is indicated for the treat-
ment of chronic lymphocytic leukaemia, and has been shown
to be active in relapsed/refractory disease and in previously
untreated patients [36]. Furthermore, alemtuzumab has
shown efﬁcacy in preventing GVHD in patients undergoing
allogeneic HSCT [36].
An increased incidence of CMV infection (as deﬁned by
positive pp65 antigenaemia and/or plasma PCR for CMV
DNA) associated with the use of alemtuzumab has been doc-
umented in 15–66% of patients with lymphoproliferative dis-
eases examined [36–38]. A particularly high incidence of
CMV infection (50–85%) has been observed in patients
receiving alemtuzumab for T-cell depletion after non-my-
eloablative allogeneic HSCT [39,40]. The incidence of symp-
tomatic CMV infection was as high as 18% [37–39], and
sporadic cases of CMV disease have been reported [37,38].
The majority of CMV infections occurred within the ﬁrst
3 months of alemtuzumab therapy, when the CD4 and CD8
cell counts were profoundly reduced [37–41]. Several rec-
ommendations [37,41,42] have been made: (i) weekly moni-
toring of CMV by pp65 antigenaemia and/or by PCR during
alemtuzumab therapy; (ii) therapy with ganciclovir or val-
ganciclovir for symptomatic patients with positive pp65 anti-
genaemia and/or CMV DNA; the approach to the
asymptomatic patient with a rising CMV viral load is less
clear, but, until deﬁnitive data become available, it seems
prudent to administer pre-emptive therapy; the appropriate
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duration of antiviral therapy is unknown, but anti-CMV treat-
ment should be given for 14–21 days until CMV viral load
negativity; (iii) in cases of symptomatic infection with increas-
ing CMV viral load, alemtuzumab therapy should be stopped
and restarted following successful anti-CMV therapy and sus-
tained negative CMV test results; and (iv) anti-CMV prophy-
laxis with antiviral drugs, including valganciclovir, high doses
of acyclovir, and valacyclovir [43], should be given during ale-
mtuzumab therapy and for at least 2 months after the end of
treatment.
The use of rituximab as single agent does not appear to
increase the incidence of CMV infection, whereas an
increased rate of CMV reactivation has been reported after
its use in combination with cytotoxic drugs [19,31]; in the
setting of autologous HSCT, the risk of developing CMV
infection has been reported to be signiﬁcantly higher in ritux-
imab-treated patients than in non-rituximab-treated patients
[44].
EBV
Given the potency of alemtuzumab in depleting lymphocytes,
there is an obvious concern about the development of a
post-transplantation lymphoproliferative disease (PTLD) sec-
ondary to infection with EBV. In patients undergoing alloge-
neic HSCT, risk factors include the mismatch between the
donor and the recipient, depletion of T-cells from the graft
(use of alemtuzumab or anti-thymocyte globulin), and the
severity and duration of the immunosuppression used to
prevent GVHD [45]. In recipients of solid organ transplants,
the risk factors for developing a PTLD include the degree of
immunosuppression and the development of primary infec-
tion after transplantation [45]. Of 547 solid organ transplant
recipients treated with alemtuzumab without antiviral pro-
phylaxis, 56 (10%) developed 62 opportunistic infections,
including three (5%) EBV infections with PTLD [46]. The
association between T-cell depletion and a possible risk of
PTLD supports the monitoring of EBV-seronegative recipi-
ents of organs from seropositive donors by quantitative
molecular tests monthly for at least 1 year after induction
therapy. For patients with detectable EBV DNA, the level of
immunosuppression should be decreased and the frequency
of monitoring of EBV DNA should be increased [47]. More
than 50% of cases of PTLD respond to rituximab therapy,
but this treatment may fail because of downregulation of the
CD20 antigen on malignant B-cells or because of the
absence of efﬁcient antibody-mediated cellular toxicity effec-
tors. The pre-emptive use of rituximab and adoptive immu-
notherapy with donor-collected EBV-cytotoxic T-cells has
been shown to reduce the mortality of PTLD (reviewed in
[48]). Data on the efﬁcacy of infusion of donor lymphocytes
are promising, with an overall survival rate of 41% (reviewed
in [48,49]).
In patients receiving anti-TNF-a therapy, sporadic cases of
EBV-related lymphoproliferative disease have been observed;
cessation of therapy resulted in a regression of the lym-
phoma [50]; however, recent studies have highlighted a lack
of a convincing association [51].
HHV-8
HHV-8 infection associated with Kaposi’s sarcoma has been
observed in two renal transplant recipients receiving ritux-
imab [52]; in contrast, rituximab has been successfully used
as therapy for HHV-8 infection in a renal transplant recipient
with severe HHV-8 primary infection [53]. Finally, in a pro-
spective study, no HHV-8 reactivation was documented in
60 patients receiving inﬂiximab for active Crohn’s disease
[54]. The consequences of mAb therapies in these settings
are still unclear.
Conclusions
Patients receiving the currently available mAbs are at high
risk for the reactivation of latent viral infections and for the
development of exogenous viral infections. Patients receiving
biological agents should therefore be closely monitored
before the start of therapy, and should receive prophylactic
or pre-emptive therapy for the viral infections if monitoring
is positive. Physicians dealing with patients receiving mAbs or
immunomodulating therapies should pro-actively consider
that viral infections may present with atypical signs and
symptoms.
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